We are a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor currently in development for MDS and AML. We are also developing ME-344, a novel mitochondrial inhibitor, and PWT143, a highly selective PI3K delta inhibitor.
[ Read more ]
MEI Pharma Completes Public Offering of Common Stock
[ December 17, 2014 ]
MEI Pharma Announces Election of Kevan Clemens to Board of Directors
[ December 4, 2014 ]
MEI Pharma Advances Clinical Study of ME-344 in Small Cell Lung and Ovarian Cancers [ October 29, 2014 ]
Click here for our 2014 Annual Review